|Bid||29.13 x 1000|
|Ask||29.23 x 1100|
|Day's Range||28.16 - 29.62|
|52 Week Range||13.54 - 32.10|
|Beta (5Y Monthly)||1.55|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||37.40|
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 5.26% and 65.04%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or the "Company") today reported financial results for the first quarter of 2021 ended March 31, 2021 and provided a corporate update.
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported that on April 30, 2021, it issued an inducement award to Ramesh Bhatt, the Company's recently hired Vice President, Discovery Biology and Translational Research, in accordance with the terms of Dr. Bhatt's employment offer letter. The award was granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020.